dihomoγlinolenic acid

Ethyl dihomo-γ-linolenic acid ethyl ester (ethyl DGLA), an ω-6 fatty acid intermediate ester form, elevates prostaglandin E1(PGE1) and PGE2 secretion in rabbit renal papilla when administered dietarily at a dosage of 1 g/kg per day for 25 days. Additionally, this dosage of ethyl DGLA increases triglyceride levels and enhances the proportion of 20:3ω6 and 20:4ω6 phospholipids in the renal medulla of rabbits. Ethyl DGLA formulations have been employed in managing eczema and inflammatory disorders.

Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium, a 20-carbon ω-6 fatty acid, exhibits anti-inflammatory and anti-proliferative properties. It has been shown to mitigate atherosclerosis in the apolipoprotein E deficient mouse model system [1] [2] [3].

Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic acid which has anti-inflammatory and anti-proliferative effects.

Dihomo-γ-linolenic acid (DGLA) is a fatty acid widely found in plants with antitumor and antiproliferative effects, inhibits the growth of xenograft tumor cells, and can be used in the study of inflammation-related diseases such as rheumatoid arthritis, atherosclerosis, and atopic dermatitis.